Skip to main content
. 2014 Dec 9;16(12):1121–1127. doi: 10.1016/j.neo.2014.11.006

Figure 2.

Figure 2

SChLAP1 expression increases with prostate cancer progression. (A) Histogram representation of mean SChLAP1 ISH product score for benign prostatic glands (Benign), clinically localized prostate cancer (PCA), and lethal mCRPC (METS) in a large TMA cohort. Error bars represent standard deviation. SChLAP1 expression is significantly associated with prostate cancer progression, from benign glands to clinically localized prostate cancer to mCRPC (P < .001). (B) Histogram representation of proportion of clinically localized prostate cancer with negative (ISH product score = 0), low (ISH product score > 0 and < 100), or high (ISH product score ≥ 100) SChLAP1 expression, stratified by GS. High SChLAP1 expression is associated with increasing GS in clinically localized prostate cancer.